Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: A multicenter external validation
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES28(8) · pp.671 · 2021
- 피인용
- Web of Science 14Scopus 13
- FWCI (Scopus)
- 0.75
- JCR IF
- JCR 2020 7.027
- ISSN
- 1868-6974
저자
- Choi, Munseok제1저자Department of Surgery, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin-si, Korea
- Chong, Jae UkDepartment of Surgery, National Health Insurance Service Ilsan Hospital, Goyang, Korea
- Hwang, Ho KyoungDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- 서형일Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
- 양광호Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea
- 류제호Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea
- Roh, YounghoonDepartment of Surgery, Dong-A University Medical Center, Dong-A University College of Medicine, Busan, Korea
- Kim, Dong HyunDepartment of Surgery, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea
- Lee, Jin HoDepartment of Surgery, National Health Insurance Service Ilsan Hospital, Goyang, Korea
- Lee, Woo JungDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Choi, Sung Hoon교신저자Division of Hepatobiliary and Pancreas, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongam-si, Korea
- Kang, Chang Moo교신저자Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
초록
Background Adjuvant therapy is beneficial in prolonging survival in patients with pancreatic ductal adenocarcinoma (PDAC). However, no clear guidelines are available on the oncologic effect of adjuvant therapy in resected invasive intraductal papillary mucinous neoplasms (inv-IPMN). Methods In total, 551 patients with PDAC and 67 patients with inv-IPMN of the pancreas were reviewed. For external validation, 46 patients with inv-IPMN from six other Korean institutions were enrolled. Propensity score-matched analysis and stage-matched survival analysis were conducted. Results The mean follow-up durations in the inv-IPMN and PDAC groups were 43.36 months (SD, 42.34 months) and 43.35 months (SD, 35.62 months), respectively. The 5-year overall survival (OS) was significantly better in the resected inv-IPMN group than in the PDAC group in the overall stage-matched analysis (P < .001). In the inv-IPMN cohort, OS was better in the surgery alone group (P = .042). In subgroup analysis, no significant survival difference was found between the adjuvant therapy and surgery alone groups according to the stage (stage I; P = .285, stage II or III; P = .077). Multicenter external validation did not show a better OS in the adjuvant therapy group (P = .531). On multivariable analysis, only perineural invasion (PNI) was identified as an adverse prognostic factor in resected inv-IPMN (HR 4.844; 95% CI 1.696-13.838, P = .003). Conclusions inv-IPMN has a more indolent course than PDAC. Current strategy of adjuvant therapy may not improve the OS in patients with resected inv-IPMN. Further investigations on the potential role of adjuvant therapy in inv-IPMN are mandatory.
키워드
pancreatic IPMNpancreas canceradjuvant chemotherapyinvasive IPMNmulticenter studyADENOCARCINOMACARCINOMASURVIVALIPMNGEMCITABINEPROGNOSIS
식별자
- Scopus EID
- 2-s2.0-85107811237
- WoS UID
- 000661184500001



로그인
연구물 목록으로